Fluticasone

Results: 264



#Item
211IMPORTANT REVISIONS TO PRESCRIBING INFORMATION FOR SEREVENT® (salmeterol xinafoate) AND ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) GlaxoSmithKline PO Box 13398

IMPORTANT REVISIONS TO PRESCRIBING INFORMATION FOR SEREVENT® (salmeterol xinafoate) AND ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) GlaxoSmithKline PO Box 13398

Add to Reading List

Source URL: www.fda.gov

Language: English
212Consumer Health Information www.fda.gov/consumer www.fda.gov/consumer/updates/asthmameds051308.html  FDA Safety Update:

Consumer Health Information www.fda.gov/consumer www.fda.gov/consumer/updates/asthmameds051308.html FDA Safety Update:

Add to Reading List

Source URL: www.fda.gov

Language: English
213Adult Asthma Information Pack

Adult Asthma Information Pack

Add to Reading List

Source URL: www.mhcs.health.nsw.gov.au

Language: English
214Consistency of Pregnancy Labeling Across Different Therapeutic Classes

Consistency of Pregnancy Labeling Across Different Therapeutic Classes

Add to Reading List

Source URL: www.fda.gov

Language: English
215FOOD AND DRUG ADMINISTRATION (FDA)

FOOD AND DRUG ADMINISTRATION (FDA)

Add to Reading List

Source URL: www.fda.gov

Language: English
216U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may

Add to Reading List

Source URL: www.fda.gov

Language: English
217The following is a list of the most commonly prescribed drugs. It represents an abbreviated version of the drug list (formulary) that is at the core of your prescription-drug benefit plan. The list is not all-inclusive a

The following is a list of the most commonly prescribed drugs. It represents an abbreviated version of the drug list (formulary) that is at the core of your prescription-drug benefit plan. The list is not all-inclusive a

Add to Reading List

Source URL: www.emblemhealth.com

Language: English - Date: 2014-07-15 16:19:36
218[removed]Federal Register / Vol. 68, No[removed]Tuesday, July 8, [removed]Notices TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued Item

[removed]Federal Register / Vol. 68, No[removed]Tuesday, July 8, [removed]Notices TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued Item

Add to Reading List

Source URL: www.fda.gov

Language: English
219Age and Risks of FDA−Approved Long-Acting β2-Adrenergic Receptor Agonists Ann W. McMahon, Mark S. Levenson, Bradley W. McEvoy, Andrew D. Mosholder and Dianne Murphy Pediatrics; originally published online October 24,

Age and Risks of FDA−Approved Long-Acting β2-Adrenergic Receptor Agonists Ann W. McMahon, Mark S. Levenson, Bradley W. McEvoy, Andrew D. Mosholder and Dianne Murphy Pediatrics; originally published online October 24,

Add to Reading List

Source URL: pediatrics.aappublications.org

Language: English
220FLUTICASONE PROPIONATE OINTMENT, 0.005% For Dermatologic Use Only Not for Ophthalmic Use  DESCRIPTION:

FLUTICASONE PROPIONATE OINTMENT, 0.005% For Dermatologic Use Only Not for Ophthalmic Use DESCRIPTION:

Add to Reading List

Source URL: www.fougera.com

Language: English - Date: 2009-11-24 10:11:58